Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 116 results for rheumatoid arthritis

  1. Spondyloarthritis (QS170)

    This quality standard covers diagnosing and managing spondyloarthritis in adults aged 16 and over. It describes high-quality care in priority areas for improvement.

  2. Analgesics:- What is the clinical and cost effectiveness of analgesic drugs other than non-steroidal antiinflammatory drugs (NSAIDs) in adults with rheumatoid arthritis (RA) whose pain or stiffness control is not adequate?

    than non-steroidal antiinflammatory drugs (NSAIDs) in adults with rheumatoid arthritis (RA) whose pain or stiffness control is not...

  3. Multiple long-term conditions: medication review (IND207)

    This indicator covers the percentage of patients with moderate or severe frailty and/or multimorbidity who have received a medication review in the last 12 months which is structured, has considered the use of a recognised tool and taken place as a shared discussion. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM186

  4. Skin involvement in systemic sclerosis: rituximab (ES7)

    Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making

  5. Tofacitinib for treating juvenile idiopathic arthritis (TA735)

    Evidence-based recommendations on tofacitinib for treating juvenile idiopathic arthritis.

  6. Avtozma (tocilizumab biosimilar) for treating moderate to severe rheumatoid arthritis in people aged 18 to 75 [TSID11848]

    Topic prioritisation

  7. Midcarpal hemiarthroplasty for wrist arthritis (IPG663)

    Evidence-based recommendations on midcarpal hemiarthroplasty for wrist arthritis in adults. This involves using a metal implant to create an artificial wrist joint, to relieve pain and maintain movement.

  8. Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain (NG193)

    This guideline covers assessing all chronic pain (chronic primary pain, chronic secondary pain, or both) and managing chronic primary pain in people aged 16 years and over. Chronic primary pain is pain with no clear underlying cause, or pain (or its impact) that is out of proportion to any observable injury or disease.

  9. Past appeals and decisions

    Past technology appraisal appeals and decisions

  10. Lateral elbow resurfacing for arthritis (IPG705)

    Evidence-based recommendations on lateral elbow resurfacing for arthritis. This involves inserting an implant into the 2 bones that form the joint at the outer part of the elbow, under general anaesthetic.

  11. Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)

    Evidence-based recommendations on certolizumab pegol (Cimzia) and secukinumab (Cosentyx) for treating active psoriatic arthritis in adults.

  12. Total wrist replacement (IPG271)

    Evidence-based recommendations on total wrist replacement. This involves creating an artificial wrist joint consisting of metal implants attached to the end of the arm and to the hand, separated by a spacer to allow movement.

  13. Remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn's disease and ulcerative colitis (ES35)

    Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis

  14. Ustekinumab for treating active psoriatic arthritis (TA340)

    Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.